Amneal Pharmaceuticals, Inc. 4

Executive Vice President Andrew S. Boyer transferred 152,426 shares of Amneal Pharmaceuticals Class A Common Stock as a gift to a family trust, leaving him with 273,646 directly owned shares.

On August 21, 2026, Executive Vice President Andrew S. Boyer reported a disposition of 152,426 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock, characterized as a gift to a trust established for the benefit of certain family members, in which he does not serve as trustee. The Form 4 indicates that this was a non-market, no‑price transaction coded as a gift (transaction code G), and thus there is no sale proceeds or transaction value implied. Following the transfer, Boyer’s direct beneficial ownership in Amneal stood at 273,646 shares. This transaction appears to be driven by estate or family planning rather than a change in economic exposure to the company’s equity.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

fda

Accession

0001628280-26-058918

Alert Tier

4